TAMPA – Wellgistics Health, Inc. (NASDAQ:WGRX) has begun integrating its EinsteinRx artificial intelligence platform into pharmacy client point-of-sale systems, according to a press release issued Wednesday. The micro-cap company, currently valued at approximately $42 million, has seen its stock price decline nearly 89% over the past year, though it has shown a modest 5% gain year-to-date.
The health information technology company aims to optimize its onboarding process before scaling up marketing efforts to its pharmacy clients. Wellgistics has set a target to onboard up to 500 pharmacies monthly into its formal Wellgistics Pharmacy Network by the end of 2026.
“We have already started the Wellgistics Pharmacy Network integration process with our closest pharmacy customers and are currently optimizing the onboarding process to make it as seamless as possible for pharmacists,” said Prashant Patel, President and Interim-CEO of Wellgistics Health.InvestingPro analysis indicates WGRX faces significant financial challenges, with short-term obligations exceeding liquid assets and weak gross profit margins. Investors can access additional insights and 8 more ProTips with a subscription.
The company reports that pharmacies joining the network will gain access to patient-specific health information from provider databases alongside prescription optimization tools. These resources are designed to help pharmacists advise on prescription drug selection and related products.
Wellgistics plans to focus initially on the diabetes drug Brenzavvy before expanding to other medications for patients with cardiometabolic conditions, including those prescribed GLP-1 agonist drugs and treatments for Long COVID. Despite impressive revenue growth of nearly 496% in the last twelve months, the company reported revenue of just $34.08 million and remains unprofitable with a negative EBITDA of $69.09 million.
The company is also assessing resource requirements for developing PharmacyChain, its blockchain-enabled healthcare smart contracts platform, which aims to reduce administrative burdens in healthcare delivery and improve insurance reimbursement processes. The company’s current ratio of 0.39 suggests potential liquidity challenges as it pursues this development.
Wellgistics currently connects over 6,500 pharmacies with more than 200 manufacturers through its platform, which offers wholesale distribution, digital prescription routing, and various hub services.
The information in this article is based on a company press release statement.
In other recent news, Wellgistics Health reported a wider third-quarter loss primarily due to increased stock-based compensation costs. The company also announced the commercial launch of its diabetes prescription drug, Brenzavvy, targeting the $16 billion SGLT-2 inhibitor market in the United States. This launch aims to address the needs of the 33 million type II diabetics, particularly those who are uninsured or underinsured. Additionally, Wellgistics Health received a notice from the Nasdaq Listing Qualifications Staff regarding a deficiency in meeting the minimum bid price requirement of $1.00 per share. The company has until June 8, 2026, to regain compliance with this listing rule. In another development, Wellgistics Health has licensed smart contracts technology from DataVault AI for use in its PharmacyChain and EinsteinRx initiatives. This move is part of the company’s strategy to enhance its digital prescription drug tracking capabilities. These recent developments reflect Wellgistics Health’s ongoing efforts to expand its product offerings and technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
